Greencore
No. 2 Northwood Avenue, Northwood Business Park, Santry, Dublin, D09 X5N9, Ireland
Overview
Greencore Group plc is a leading international manufacturer of convenience foods. They have 22 convenience foods manufacturing sites in the UK and the US; and employ in the region of 12,000 people. The Convenience Foods Division provides a wide range of chilled, frozen and ambient foods to major retail, manufacturing and foodservice customers in the UK and Ireland, as well as many in Continental Europe, the US and beyond. They have long-standing experience in customer brand as well as providing a selection of house and licensed brands. The Division consists of six manufacturing category businesses comprising 15 sites in the UK and seven in the United States. They also operate a UK nationwide chilled van distribution fleet to service individual outlets. The Ingredients & Related Property Division comprises Trilby Trading and associate molasses companies as well as a specialist property team that is working to maximise the value of the Group's property assets.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 4
Sector focus
- Food Processing
- Manufacturing
Investment portfolio
- A Plus
Led · Seed · Jan 2024
A-SEEDS develops CAR-T cell therapies using piggyBac transposon technology, which the company says yields enhanced and prolonged therapeutic effects and lowers production costs. It has completed preclinical studies for two CAR-T products and is advancing phase 1 clinical trials in collaboration with Shinshu University. The company is building a diversified CAR-T pipeline and focusing on cost-efficient manufacturing. Founded in April 2020 and based in Matsumoto, Nagano, A-SEEDS secured ¥440 million in seed funding to support technology transfers for CAR-T production and to strengthen its organizational and R&D capabilities. The funds will underwrite preparation for U.S. clinical trials planned after 2024, and the company is planning a larger capital raise to support those trials. Company capital is listed at ¥36 million.